Menu
Warfarin is indicated for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.
Warfarin is indicated for the prophylaxis after insertion of prosthetic heart valves.
Warfarin is indicated for the prophylaxis and treatment of venous thrombosis and pulmonary embolism.
Warfarin is indicated for transient cerebral ischaemic attacks.
Adults and elderly patients: The typical induction dose of warfarin is 10 mg daily for 2 days, but this should be tailored to individual requirements. Baseline prothrombin measurements (PT) should be taken before beginning therapy with warfarin.
The daily maintenance dose of warfarin is usually 3 to 9 mg taken at the same time each day. The exact maintenance dose for an individual is dependent on the prothrombin time or other appropriate coagulation tests. The maintenance dose is omitted if the prothrombin time is excessively prolonged. Once the maintenance dose is stabilised in the therapeutic range, it is rarely necessary to alter it.
In emergencies, anticoagulant therapy should be initiated with heparin and warfarin together. Where there is less urgency, as in patients disposed to or at special risk of thromboembolism, anticoagulant therapy may be initiated with warfarin alone.
Concomitant heparin therapy affects the results of control tests and should be discontinued at least six hours before the first test is carried out.
Control is established with INR monitoring at regular intervals and subsequent warfarin maintenance dosage further adjusted according to the results obtained.
Paediatric population: No data are available.
Infections and infestations
Fever
Immune system disorders
Hypersensitivity
Nervous system disorders
Cerebral haemorrhage; Cerebral subdural haematoma
Vascular disorders
Haemorrhage
Respiratory, thoracic and mediastinal disorders
Haemothorax, epistaxis
Gastrointestinal disorders
Gastroinestinal haemorrhage, rectal haemorrhage, haematemesis; pancreatitis; diarrhoea; nausea; vomiting; melaena
Hepatobiliary disorders
Jaundice; hepatic dysfunction
Skin and subcutaneous disorders
Rash; alopecia; purpura; ‘purple toes’ syndrome; erythematous swollen skin patches leading to ecchymosis, infarction and skin necrosis; calciphylaxis
Renal and Urinary disorders
Haematuria; anticoagulant-related nephropathy
If a rapid antithrombotic effect is needed, heparin treatment must be initiated first. After this, heparin treatment is continued along with the initiated warfarin treatment for at least 5 to 7 days until the INR has been at target level for at least two days.
Interactions
There is a large risk for interactions when warfarin is used concomitantly with other drugs. An intensified monitoring of the therapeutic response to warfarin is therefore recommended when treatment with other drugs is initiated or withdrawn during warfarin treatment.
Genetic variations
Elimination of warfarin is slower in patients with certain mutations in the gene for the enzyme CYP2C9 metabolising (S)-warfarin. These patients only require a low maintenance dose and have a risk of excessive bleeding if a high initial dose is given. In addition, it will take longer to achieve the new efficacy level after adjusting the dose. Also patients with genetic variations of the enzyme VKOR may require lower doses due to increased sensitivity to warfarin.
Resistance
Resistance to warfarin is a very rare phenomenon. Only case reports have been published on that. These patients need 5 to 20 fold warfarin doses to achieve therapeutic response. If the response of the patient to warfarin treatment is poor, other more plausible causes should be ruled out: patient incompliance, interaction with other medicaments or food, and also laboratory errors.
Coumarin necrosis
To avoid coumarin necrosis patients with a hereditary deficiency of antithrombotic protein C or S must first be treated with heparin. Concomitantly initiating warfarin loading doses must not exceed 5 mg. Heparin treatment must be continued for 5 to 7 days as described above.
Store below 30°C and protect from light and moisture.
Keep out of reach of children.
1 x10 Alu/PVC blister
Warfarin Tablets BP 5 mg are available in an Alu/PVC blister of 10 tablets. Such 01 blister in a carton with pack insert.
Contact us directly to receive full information on the product, the formulation, the science behind it, stability data, and more. Our Business Development Manager is a click away.
Questions are useful tools, they open lines of communication; give us information; improve interactions, facilitate analysis, and many more.
We have below MOQ for:
We do ready the product within 45-60 days after product artwork confirmation from your side. So, including transit time you can get the product within 90 days maximum, either by Air or Sea route.
A product's “shelf life” generally means the length of time you can expect a product to look and act as expected and to stay safe for use. This length of time varies, depending on the type of product, how it is used, and how it is stored.
Our products come with a minimum of 24 months to a maximum of 36 months of shelf life.
For, Primary packaging we use aluminium foil with 20 to 50 micron size and PVC foil with 350 to 400 micron depending on product characteristics and stability.
For, Secondary packing we do use 300 to 400 GSM FFB Card board.
For, Tertiary packing we do us 7 ply 150 GSM corrugated boxes to prevent the damage during transits.
Yes, we do have available for all dossier documents according to GMP guidelines for the respective country. We do also provide COPP and Free sale certificates (FSC) on demand to customers for special import permit type of commercial orders.
Conical Pharmaceuticals is a professionally managed and dynamic organization with decades of experience in the pharmaceutical field. With a desire of providing opportunities for a better life, we work very hard to bring quality drugs to our customers. We have instilled a level of trust and confidence amongst our clients by supplying the best quality products.